Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms.

By A. Quintás-Cardama, K. Vaddi, Phillip C. C. Liu, T. Manshouri, Jun Li, P. Scherle, E. Caulder, X. Wen, Yanlong Li, P. Waeltz and 11 more. Blood, 2010

820 citations recorded by the source corpus.

Subfields: Genetics, Molecular Biology, Rheumatology

View Paper: https://www.semanticscholar.org/paper/dc938b4ccc3b59e6bc4840a17a7d1cd0a104c2d1

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. J. Kirkland

In Molecular Biology

1. T. Tchkonia
2. Gautam Sethi
3. J. Kirkland

Citations in the corpus

• JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. (2012, neutral): “Grade 1 27 (39) 9 (13) 14 (20) 2 (3) 1 (1)”
• JAK inhibition alleviates the cellular senescence-associated secretory phenotype and frailty in old age (2015, background): “The JAK family has four members: JAK1, JAK2, JAK3, and tyrosine kinase 2 (TYK2).”
• Targeting the STAT3 signaling pathway in cancer: role of synthetic and natural inhibitors. (2014, background): “Additionally, it was found that diosgenin suppressed the constitutive phosphorylation of JAK1 and JAK2 in a time-dependent manner.”